Article Versions Notes

Chen W-S, Luo S-D, Chiu T-J, Wang Y-M, Chen W-C, Chien C-Y, Fang F-M, Huang T-L, Li S-H. Ribophorin II Overexpression Is Associated with Poor Response to Induction Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil in P16-Negative Locally Advanced Head and Neck Squamous Cell Carcinoma. Journal of Clinical Medicine. 2021; 10(18):4118. https://doi.org/10.3390/jcm10184118

Chen, Wei-Shan, Sheng-Dean Luo, Tai-Jan Chiu, Yu-Ming Wang, Wei-Chih Chen, Chih-Yen Chien, Fu-Min Fang, Tai-Lin Huang, and Shau-Hsuan Li. 2021. "Ribophorin II Overexpression Is Associated with Poor Response to Induction Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil in P16-Negative Locally Advanced Head and Neck Squamous Cell Carcinoma" Journal of Clinical Medicine 10, no. 18: 4118. https://doi.org/10.3390/jcm10184118

Chen, W.-S., Luo, S.-D., Chiu, T.-J., Wang, Y.-M., Chen, W.-C., Chien, C.-Y., Fang, F.-M., Huang, T.-L., & Li, S.-H. (2021). Ribophorin II Overexpression Is Associated with Poor Response to Induction Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil in P16-Negative Locally Advanced Head and Neck Squamous Cell Carcinoma. Journal of Clinical Medicine, 10(18), 4118. https://doi.org/10.3390/jcm10184118